TERNS PHARMACEUTICALS INC (TERN) Fundamental Analysis & Valuation

NASDAQ:TERN • US8808811074

Current stock price

48.44 USD
-0.62 (-1.26%)
At close:
48.51 USD
+0.07 (+0.14%)
After Hours:

This TERN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. TERN Profitability Analysis

1.1 Basic Checks

  • TERN had negative earnings in the past year.
  • In the past year TERN has reported a negative cash flow from operations.
  • In the past 5 years TERN always reported negative net income.
  • In the past 5 years TERN always reported negative operating cash flow.
TERN Yearly Net Income VS EBIT VS OCF VS FCFTERN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • TERN has a Return On Assets (-31.31%) which is comparable to the rest of the industry.
  • TERN has a Return On Equity of -33.24%. This is in the better half of the industry: TERN outperforms 61.46% of its industry peers.
Industry RankSector Rank
ROA -31.31%
ROE -33.24%
ROIC N/A
ROA(3y)-26.35%
ROA(5y)-28.14%
ROE(3y)-27.6%
ROE(5y)-31.38%
ROIC(3y)N/A
ROIC(5y)N/A
TERN Yearly ROA, ROE, ROICTERN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

1.3 Margins

  • TERN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TERN Yearly Profit, Operating, Gross MarginsTERN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K -5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. TERN Health Analysis

2.1 Basic Checks

  • TERN has more shares outstanding than it did 1 year ago.
  • TERN has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for TERN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TERN Yearly Shares OutstandingTERN Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
TERN Yearly Total Debt VS Total AssetsTERN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • TERN has an Altman-Z score of 175.42. This indicates that TERN is financially healthy and has little risk of bankruptcy at the moment.
  • TERN has a Altman-Z score of 175.42. This is amongst the best in the industry. TERN outperforms 98.44% of its industry peers.
  • There is no outstanding debt for TERN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 175.42
ROIC/WACCN/A
WACCN/A
TERN Yearly LT Debt VS Equity VS FCFTERN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 19.52 indicates that TERN has no problem at all paying its short term obligations.
  • TERN has a better Current ratio (19.52) than 89.58% of its industry peers.
  • TERN has a Quick Ratio of 19.52. This indicates that TERN is financially healthy and has no problem in meeting its short term obligations.
  • TERN has a better Quick ratio (19.52) than 90.10% of its industry peers.
Industry RankSector Rank
Current Ratio 19.52
Quick Ratio 19.52
TERN Yearly Current Assets VS Current LiabilitesTERN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. TERN Growth Analysis

3.1 Past

  • TERN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.71%, which is quite good.
EPS 1Y (TTM)12.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, TERN will show a decrease in Earnings Per Share. The EPS will decrease by -7.09% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y2.67%
EPS Next 2Y-3.91%
EPS Next 3Y-11.19%
EPS Next 5Y-7.09%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TERN Yearly Revenue VS EstimatesTERN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
TERN Yearly EPS VS EstimatesTERN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

0

4. TERN Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TERN. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TERN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TERN Price Earnings VS Forward Price EarningsTERN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TERN Per share dataTERN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

  • TERN's earnings are expected to decrease with -11.19% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.91%
EPS Next 3Y-11.19%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TERN Dividend Analysis

5.1 Amount

  • No dividends for TERN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TERN Fundamentals: All Metrics, Ratios and Statistics

TERNS PHARMACEUTICALS INC

NASDAQ:TERN (3/20/2026, 8:24:52 PM)

After market: 48.51 +0.07 (+0.14%)

48.44

-0.62 (-1.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-10
Earnings (Next)03-31
Inst Owners116.51%
Inst Owner Change22.67%
Ins Owners0.57%
Ins Owner Change10.86%
Market Cap5.14B
Revenue(TTM)N/A
Net Income(TTM)-94.44M
Analysts85.56
Price Target55.08 (13.71%)
Short Float %16.12%
Short Ratio7.85
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.4%
Min EPS beat(2)10.7%
Max EPS beat(2)12.1%
EPS beat(4)4
Avg EPS beat(4)13.96%
Min EPS beat(4)8.96%
Max EPS beat(4)24.07%
EPS beat(8)8
Avg EPS beat(8)12.04%
EPS beat(12)10
Avg EPS beat(12)9.13%
EPS beat(16)14
Avg EPS beat(16)10.27%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.83%
PT rev (3m)77.37%
EPS NQ rev (1m)3.63%
EPS NQ rev (3m)3.31%
EPS NY rev (1m)0.57%
EPS NY rev (3m)0.17%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 18.11
P/tB 18.11
EV/EBITDA N/A
EPS(TTM)-1.03
EYN/A
EPS(NY)-1.22
Fwd EYN/A
FCF(TTM)-0.74
FCFYN/A
OCF(TTM)-0.74
OCFYN/A
SpS0
BVpS2.67
TBVpS2.67
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -31.31%
ROE -33.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.35%
ROA(5y)-28.14%
ROE(3y)-27.6%
ROE(5y)-31.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -0.71%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.52
Quick Ratio 19.52
Altman-Z 175.42
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)29.77%
Cap/Depr(5y)60.94%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.57%
EPS Next Y2.67%
EPS Next 2Y-3.91%
EPS Next 3Y-11.19%
EPS Next 5Y-7.09%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-7.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-6.92%
EBIT Next 3Y-16.74%
EBIT Next 5Y-9.07%
FCF growth 1Y-31.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.76%
OCF growth 3YN/A
OCF growth 5YN/A

TERNS PHARMACEUTICALS INC / TERN Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for TERNS PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 3 / 10 to TERN.


What is the valuation status of TERNS PHARMACEUTICALS INC (TERN) stock?

ChartMill assigns a valuation rating of 0 / 10 to TERNS PHARMACEUTICALS INC (TERN). This can be considered as Overvalued.


How profitable is TERNS PHARMACEUTICALS INC (TERN) stock?

TERNS PHARMACEUTICALS INC (TERN) has a profitability rating of 1 / 10.


What is the financial health of TERNS PHARMACEUTICALS INC (TERN) stock?

The financial health rating of TERNS PHARMACEUTICALS INC (TERN) is 8 / 10.